title: Clinicopathological features of CA19-9-producing gastric cancer.
abstract: OBJECTIVE
  The aims of this study were to define CA19-9-producing gastric cancer and investigate its clinicopathological features.
  
  
  METHODS
  Twenty-three patients showing high preoperative serum CA19-9 levels (> or = 38 U/mL) were enrolled in this retrospective cohort study. The CA19-9 cut-off level was determined on the basis of receiver operating characteristic analysis of CA19-9 levels obtained from patients having survived for 3 years after surgery. Patients in whom the CA19-9 level was the cut-off level or higher were defined as having CA19-9-producing gastric cancer (Group A), and their clinicopathological features were compared with those of patients showing CA19-9 levels less than the cut-off level (Group B).
  
  
  RESULTS
  The preoperative serum CA19-9 cut-off level was set at 77 U/mL. In Group A, lymph node metastasis was seen in all 11 patients, with the incidence being higher than that in Group B (p <0.001). The number of patients with stage III or greater disease was 10 in Group A, compared with only 3 in Group B (p < 0.001). The independent prognostic factors were preoperative serum CA19-9 levels, venous invasion and tumor stage.
  
  
  CONCLUSIONS
  CA19-9-producing gastric cancer is a type of gastric cancer with poor prognosis and characterized by preoperative serum CA19-9 > or = 77 U/mL.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yajima
authors.forename: Noburo
authors.initials: N
authors.lastname: Omura
authors.forename: Kazuo
authors.initials: K
authors.lastname: Matai
authors.forename: Norio
authors.initials: N
authors.lastname: Mitsumori
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshida
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Yanaga
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018395:CA-19-9 Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011379:Prognosis; D013274:Stomach Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D015996:Survival Rate
chemical_list: D018395:CA-19-9 Antigen